Stonegate Capital Partners Initiates Coverage on AB Science S.A.

Got story updates? Submit your updates here. ›

Stonegate Capital Partners, a leading capital markets advisory firm, has initiated coverage on AB Science S.A., a late-stage biotech company advancing masitinib, an oral, selective tyrosine kinase inhibitor. AB Science is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML.

Why it matters

The initiation of coverage by Stonegate Capital Partners on AB Science S.A. highlights the potential of the company's lead asset, masitinib, in treating various neurological and autoimmune diseases. The combination of a treatment for ALS along with the optionality that comes with the rest of the company's portfolio makes it an exciting development to monitor.

The details

AB Science is a late-stage biotech company advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML.

• AB Science's ALS program is supported by prior Phase 2b/3 data.
• For progressive MS, the Phase 3 trial is authorized in the US and 12 EU countries with ~94 sites initiating.